Characteristics of responders and non-responders to risperidone monotherapy or
placebo in co-occurring bipolar disorder and anxiety disorder.
Author(s): Seo JS(1), Jamieson K, Cosgrove V, Gwizdowski IS, Yang H, Sheehan DV, McElroy SL,
Suppes T.
Affiliation(s): Author information:
(1)Stanford University School of Medicine, Department of Psychiatry and Behavioral
Sciences, VA Palo Alto Health Care System, 3801, Miranda Avenue (151T), Palo
Alto, CA 94304, USA.
Publication date & source: 2013, Eur Psychiatry. , 28(3):190-6
Clinical characteristics predicting response and remission to
psychopharmacological treatment of bipolar disorder (BD) and co-occurring anxiety
disorders have been understudied. We hypothesized that non-response to
risperidone or placebo in individuals with co-occurring BD and anxiety symptoms
would be associated with a more severe clinical course of BD, and certain
demographic variables. This study was a secondary analysis of a randomized,
double-blind, parallel, 8-week study comparing risperidone monotherapy and
placebo in individuals with BD plus current panic disorder, current generalized
anxiety disorder (GAD), or lifetime panic disorder (n=111) [31]. We compared
clinical characteristics of responders (50% improvement on the Hamilton Anxiety
Scale [HAM-A]) and non-responders as well as remitters (HAM-A<7) and
non-remitters in risperidone treatment (n=54) and placebo (n=57) groups. For
non-responders in the risperidone group, co-occurring lifetime panic disorder was
significantly more common than for non-responders in the placebo group. Apart
from this, no significant differences in course of illness or demographics were
found either between or across groups for patients with BD and co-occurring
anxiety symptoms receiving risperidone or placebo in this acute phase study.
|